Thermal optimized PCR coupled to CRISPR-Cas12a for rapid detection of blaOXA-1 resistance gene Authors: Ana Quiroz-Huanca, Maryhory Vargas-Reyes, Juan Diego López, Kiara Flores-Jimenez, Sofia Saldarriaga-Morán, Karla Cifuentes, Roberto Alcántara, Iddya Karunasagar, Iddya Karunasagar, Iddya Karunasagar, Iddya Karunasagar Published: 2026 ABSTRACT The β-lactams are critically important broad-spectrum antibiotics, widely used as first-line treatments; however, their effectiveness is increasingly compromised by β-lactamase enzymes. Among these, OXA-type enzymes have expanded to over 400 variants and are highly prevalent in Enterobacteriaceae. Current phenotypic and molecular detection tests have long turnaround times or require specialized equipment, respectively. In this study, we optimize a rapid molecular assay combining a PCR with modified thermal ramp rate (TRR) along with CRISPR-Cas12a fluorescence detection for blaOXA-1-harboring E. coli isolates. Using a commercial DNA Taq polymerase (TRR: 2.2 °C/s, annealing and extension hold time: 1 s), amplification time was reduced from 80 to 30 min, enabling detection within 50 min (PCR: 30 min; CRISPR: 20 min). With a locally produced enzyme (hold: 10 s), amplification time was 44 min. To demonstrate the practical application of the assay, we evaluated spiked poultry fecal samples achieving an analytical sensitivity of 8 CFU/reaction using commercial DNA Taq polymerase. The accelerated PCR:CRISPR workflow delivers results in less than one hour without compromising technical sensitivity (attomoles range), not requiring high technical expertise, and can be implemented in laboratories with basic molecular biology equipment. Introduction Antimicrobial resistance (AMR) is recognized as one of the most pressing global public health challenges, as it undermines the efficacy of antibiotic-based treatments and contributes to increased mortality from both community- and hospital-acquired infections. In 2021, it was estimated that approximately 4.71 million deaths were associated with AMR, with 1.14 million deaths directly attributable to it [1]. Among the diverse mechanisms of antibiotic resistance, β-lactamases are of particular concern due to their ability to hydrolyze penicillin, carbapenem, and even some β-lactam/β-lactamase inhibitor combinations [2]. OXA-type β-lactamases, including blaOXA-1 and its variants, encode oxacillinases that confer resistance primarily to ampicillin, and cephalosporins [3]. Notably, blaOXA-1 has been reported as one of the most prevalent blaOXA groups in clinical Enterobacteriaceae isolates globally [4,5]. Currently, diverse methods could be used to detect blaOXA genes and their associated antibiotic susceptibility. Among phenotypic antimicrobial susceptibility tests (AST), the standard disk diffusion and microdilution assays are commonly used, including modified protocols and commercial options [6–8]. While phenotypic methods are cost-effective and simple to use, their diagnostic accuracy varies depending on the β-lactamase type and the bacteria host species, especially for Gram-negative bacteria [8,9]. Molecular methods, beyond DNA sequencing, for detecting blaOXA variants include nucleic acid amplification techniques such as conventional PCR [10–13], and isothermal amplification via loop-mediated assay (LAMP) [14,15]. Despite their technical advantages, molecular tests and sequencing remain limited in low-resource settings due to high implementation costs and restricted access to related consumables [16,17]. Currently, CRISPR-Cas systems have emerged as promising molecular tools for nucleic acid detection. Among them, Cas12a is notable for its collateral cleavage activity, which enables detection using labeled probes that allow a myriad of readout approaches [18–20]. Several studies have applied CRISPR-Cas technology for detecting bacterial pathogens [21], and others for detecting antibiotic resistance genes (ARG), including β-lactamases [22,23]. Even with the competitive detection performance of CRISPR-Cas assays, most of them rely on a pre-amplification step [24]. Conventional PCR, a common pre-amplification method, relies on repeating three sequential steps of different temperatures to amplify a specific target needing long amplification times. Previous reports have introduced variations to conventional PCR by modifying ramp rates and reducing holding times to shorten amplification cycles [25,26]. In line with this evidence, the present study reports a proof-of-concept for a PCR with a modified thermal cycling protocol combined with CRISPR-Cas for the rapid fluorescent detection of blaOXA-1-harboring E.coli isolates. By utilizing spiked poultry feces as a model, we demonstrate the assay’s potential for efficient monitoring of antimicrobial resistance genes in complex matrices using basic molecular biology equipment. This dual approach substantially reduced the time-to-results while maintaining competitive analytical sensitivity. Materials and methods Oligos design A total of 46 sequences corresponding to the blaOXA-1 family were obtained from the NDARO and the CARD database (S1 File in S1 Text). The sequences were aligned using MUSCLE on the Unipro UGENE platform (version 51.0) [27] to identify a conserved region for designing the crRNA and primers, which was done using the CHOPCHOP [28] and CRISPRScan [29] programs. For crRNA prediction in both platforms, parameters were used as default for the LbCas12a with a TTTN PAM. The candidate sequences obtained from each program were consolidated. Those candidates that aligned with the sequence of the primers were discarded. For the top 10 candidate sequences, secondary structures were predicted using the ViennaRNA Web Services, with temperature et to 25°C and the NaCl concentration set to 50 mM in the energy parameter options [30]. Those sequences that showed structures with a ΔG < −5.00 kcal/mol, and a %GC >= 25% were selected. Sequence specificity was assessed by alignment against other blaOXA groups (S2 File in S1 Text), using the Unipro UGENE platform (version 51.0). Finally, the candidate with a sequence 5’-ACCAGAAGAACAAAUUCAAUUCCU-3,’ which recognizes a sequence adjacent to a PAM – TTTC, was selected. Then the LbCas12a-scafold sequence (5’-UAAUUUCUACUAAGUGUAGAU-3’) and the T7 promoter (5’-TAATACGACTCACTATAGG-3’) were added 5’-upstream. Likewise, the primers used to amplify the target region were designed in the CHOPCHOP program, forward 5’- AGCATGGCTCGAAAGTAGCTTA-3,’ and reverse 5’- GACCCCAAGTTTCCTGTAAGTG-3’ [28]. Target amplification and Optimization of PCR thermal cycling A 282 bp region of the blaOXA-1 gene from the genomic DNA of an E. coli isolate, previously characterized by whole genome sequencing [31], was amplified with conventional or modified PCR protocol. Reactions were prepared using the DreamTaq Green PCR Master Mix (2X) (Cat. N° K1081, ThermoFisher), in a final volume of 20 μL, including 0.2 μM of each primer, and 10 ng of genomic DNA. A conventional PCR reaction was included as a positive control using the same reagents and DNA target. Conventional PCR was performed as follows: initial denaturation at 95 °C for 3 min, followed by 30 cycles of 95 °C, 60 °C, and 72 °C for 30 s each, with a final extension at 72 °C for 5 min. Thermal ramp rate (TRR) was set to 0.5 °C/s, with a total amplification time of 82 minutes. For the modified PCR, the same conditions of initial denaturation and final elongation were used with cycles of 95°C and 60°C for 1 s each. Different TRR were evaluated, including 0.6 °C/s (70 min), 0.8 °C/s (56 min), 1.2 °C/s (40 min), 1.6 °C/s (34 min), and 2.2 °C/s (30 min). All reactions were carried out on the T100 Thermal Cycler (BIO-RAD, USA). The amplification products were visualized by electrophoresis (80 V for 45 min) in agarose gel (1.7%), using a pre-staining method by mixing the tracking buffer with SYBR Gold (Cat. N° S11494, ThermoFisher). The modified PCR protocol was also evaluated with a DNA Taq polymerase produced in the laboratory [31]. PCR reactions were prepared in a final volume of 20 μL, including 0.5 mM dNTPs, 2 ng/μL DNA Taq polymerase, 0.2 μM each primer, and 10 ng genomic DNA, in 1X amplification buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, 10% trehalose, 10 mM DTT, 0.1 mM EDTA, pH: 8.4, 25 °C). Different time intervals were evaluated for the amplification cycles, including 30 s, 15 s, 10 s, 5 s, and 1 s. Once the shortest time interval was defined, different TRR values were evaluated, including 0.6 °C/s (83 minutes), 0.8 °C/s (69 minutes), 1.2 °C/s (54 minutes), 1.6 °C/s (47 minutes), and 2.2 °C/s (44 minutes). The amplification products were visualized by electrophoresis (80 V for 45 min) in agarose gel (1.7%), using a pre-staining method by mixing the tracking buffer with SYBR Gold. CRISPR-Cas reaction An LbCas12a produced in the laboratory was used for the CRISPR-Cas reaction [32], following previous standardized reaction condition [33,34]. Initially, an aliquot of the crRNA was refolded at 65°C for 10 min, followed by incubation at room temperature for the same time. The crRNA:Cas complex was prepared in 10 μL of 1X NEBuffer r2.1 (50 mM NaCl, 10 mM Tris-HCl, 100 μg/mL BSA, pH 7.9–25°C), mixing 10 nM LbCas12a, 15 nM crRNA, and 200 nM of the ssDNA 5’-5FAM-TTATT-BHQ1–3’ probe. The complex was then incubated at room temperature for 10 min. In parallel, 5 μL of the amplification products were diluted in 85 μL of 1X NEBuffer r2.1 supplemented with 20 mM MgCl2. The fluorescence reading was performed on a 96-well flat-bottom black microplate (Cat. No. 23710, ThermoFisher) using a Synergy H1 (Agilent, USA) or Varioskan LUX (ThermoFisher, USA) plate multireader with an excitation wavelength at 491 nm and emission at 525 nm. Comparison between multireader instruments was performed by measuring fluorescence of a positive and negative controls (S1 Fig in S1 Text). The recorded fluorescence values were normalized (NFntc) by calculating a ratio between the fluorescence of the reactions of the samples divided by the fluorescence of the non-template control reaction (NTC). The assay specificity was evaluated against a set of E,coli isolates harboring other beta-lactamases, including blaCMY, blaCTX15, blaCTX65, blaTEM1b, and blaTEM176. Analytical performance Limit of blank (LoB). To determine the cutoff point of the assay, LoB was calculated, using 10 blaOXA-1 negative E. coli isolates that were previously characterized by whole genome sequencing [31]. The genomic DNA was amplified, and the amplification products were detected using CRISPR-Cas. For the calculation of the LoB, the mean and standard deviation (SD) of the NFntc values were calculated. Then the LoB was calculated according to the formula LoB =NFntc mean+2 ×NFntc SD, for values observed at 20 min [35]. Target concentration curve. To determine the lowest concentration of target to be detected by our modified PCR:CRISPR-Cas assay, a purified amplification product of 564 bp was titrated. This 564-bp PCR product was obtained by replacing the forward primer (5’-GGCACCAGATTCAACTTTCAAG-3’), and contains the target region for the crRNA and the primers sets to amplify the 282-bp blaOXA-1 target sequence. The template titration curve was set in moles. A 12-point target curve was prepared by serial dilution at a factor of 1:5 from 2.0 x 103 to 4.10 x 10−5 attomoles per reaction. The amplification reactions were prepared as described in the previous sections, in a final volume of 20 μL. Amplification was performed using the DreamTaq PCR Master Mix 2X Green under the following amplification conditions, 95°C for 3 min, followed by 30 cycles of 95°C for 1 s, 60°C for 1 s with a TRR of 2.2°C/s, followed by 72°C for 5 min. The Limit of Detection (LoD) was calculated following the formula LoD=LoB+2×(SD_low concentration sample) [36], where SD represents the standard deviation of the lowest target concentration that differs from the non-template control reaction. Meanwhile, amplification using the enzyme produced in the laboratory was performed under the following amplification conditions, 95°C for 3 min, followed by 30 cycles of 95 °C, 60 °C, and 72 °C for 10 s each with a TRR of 2.2°C/s, followed by 72°C for 5 min. The amplification products were visualized by electrophoresis (80 V for 45 min) in agarose gel (1.7%), using a pre-staining method by mixing the tracking buffer with SYBR Gold. In addition, 5 μL of the amplification products were used for fluorescent detection using CRISPR-Cas. Spike-in pilot test. To evaluate the performance of the assay with simulated samples, a spike-in assay was performed on chicken fecal samples, following a modified protocol from [37]. Fecal samples were obtained from a broiler farm for human consumption, located in Lurín, Lima (12°57’13.2"S 76°25’10.7"W). Sample matrix was prepared by mixing 6 g of feces with 60 mL of distilled water. A blaOXA-1-positive E. coli isolate (SRX147221841 from BioProject PRJNA821865) was grown in LB medium at 37 °C for 18 h at 150 rpm. The absorbance was then measured at 600 nm (OD600) and adjusted to a value of 0.05. Eight serial decimal dilutions were then prepared in PBS. From each dilution, 50 μL were spreaded onto LB plates to estimate colony-forming units (CFU/mL). After incubation (37°C for 16 hours), CFU counts were recorded, and dilutions corresponding to 320 and 2400 CFU/ml were selected for a 4-replicate spiking assay. From each selected dilution, 100 μL was transferred to 900 μL of fecal suspension. A volume of 250 μL from each suspension was then used for total DNA extraction, representing to 8 and 60 total CFUs, respectively. These values correspond to an expected bacterial input to the DNA extraction process. Extraction was performed using the ZymoBIOMICS™ DNA Miniprep Kit (Cat. N° D4300, Zymo Research), following the manufacturer’s protocol. DNA quantification was performed by absorbance at 260 nm in a Nanodrop One (ThermoFisher, USA). Amplification was performed using the modified PCR with the DreamTaq Green PCR Master Mix (2X), according to the conditions described in the previous sections. Finally, the amplification products were detected using the CRISPR-Cas reaction. Results Bioinformatic design Target sequence was analyzed within the blaOXA-1 gene family and found to be highly conserved, with only 4.9% single-nucleotide polymorphisms (SNPs) (41/831 nucleotides). Nucleotide variability was mainly concentrated in three regions: 180−200 bp, 290−320 bp, and 560−630 bp (S1 File in S1 Text). The forward primer hybridized within a complete SNP-free region. In contrast, the reverse primer showed a single mismatch in two of three of the blaOXA-47 sequences retrieved. Nevertheless, for both forward and reverse primers, annealing of the 3′ bases, essential for the initiation of DNA polymerization, did not show any mismatches (S1 File in S1 Text). Concerning the crRNA, only one mismatch located at the position 4 of the 5′ end was observed in the following variants, blaOXA-47, blaOXA-392, blaOXA-675, and blaOXA-1370 (S1 File in S1 Text). As this mismatch is located within what is considered the seed region (i.e., first 5-nt of the crRNA sequence following the PAM site), it could potentially affect the detection of the aforementioned blaOXA variants compared with the other members of the blaOXA-1 family. However, this remains to be evaluated, since in this study samples harboring those variants were not assessed. Specificity of the designed crRNA was analyzed against other blaOXA groups (n = 42). The analysis showed that within the seed sequence, positions +1, + 4 and +5 were highly diverse between blaOXA-1 family and the other blaOXA groups (Fig 1A). In contrast, positions +2 and +3 were more conserved across all evaluated groups, with cytosine being the most frequent nucleotide (76% and 96%, respectively). Beyond the seed region, the blaOXA-24 group showed full-length alignment with the crRNA; however, six mismatches were present along the sequence, resulting in 75% identity. Importantly, a canonical PAM (5’ TTTN 3’) was not observed upstream, and the primers did not align properly for target amplification. Taking together, the findings suggest that the detection of blaOXA-24 by our crRNA design is unlikely. Other blaOXA families like blaOXA-10, blaOXA-114 blaOXA-258, and blaOXA-364 present a PAM sequence upstream of the aligned region. Nevertheless, multiple mismatches were present, with a mean identity of 55.21%. Among the remaining groups, 39.53% showed partial alignment with the crRNA with identity percentage ranging between 54.17% to 70.83%. Remarkably, none of these alignments present a PAM region upstream of the crRNA binding site. In addition, for all evaluated blaOXA groups, the primers failed to align properly with the respective target sequences. Instead, reverse primer orientation or low coverage annealing was observed, suggesting primer specificity for the blaOXA-1-like sequences (S2 File in S1 Text). Finally. Several groups, including blaOXA-21, blaOXA-23, blaOXA-48, blaOXA-50, blaOXA-51, blaOXA-55, blaOXA-58, blaOXA-60, blaOXA-61, blaOXA-62, blaOXA-63, blaOXA-134, blaOXA-143, blaOXA-184, blaOXA-198, blaOXA-213, blaOXA-266, blaOXA-372, blaOXA-548, and blaOXA-679 did not align with the crRNA (S2 File in S1 Text). In summary, the bioinformatic analysis reveals a high level of specificity of the designed crRNA and primers for the blaOXA-1-like family. Study approach highlights. (A) Schematic representation of primers and crRNA hybridization regions in the blaOXA-1 target gene. For the target-specific crRNA sequence, the DNA sequence logo shows the positions and nucleotide variations observed between the blaOXA-1-like (n = 46) and other blaOXA families (n = 25). Nucleotide size is related to the frequency (%) in each position (Y-axis). (B) Schematic representation of the modified thermal cycling protocol (bottom) compared to conventional PCR (top). Holding times and thermal ramp rate values were modified to avoid the typical 3-step during amplification, while maintaining the denaturation and hybridization temperatures. The selected crRNA showed a low ΔG value (−2.99 kcal/mol) for its secondary structure formation, maintaining the scaffold conformation for the Cas interaction. Also, the target-specific region did not show self-complementary, and off-target sites against the human genome. Target amplification using a modified thermal cycling protocol An ideal detection method should achieve a balance between speed and result reliability. Most molecular detection assays depend on target amplification assays. While standard PCR is competitive in terms of sensitivity, it still requires ~90 min. Modifying the thermal cycling can reduce the total amplification time to ~30 min (Fig 1B), by increasing the thermal ramp rate (TRR) and reducing the holding times [38]. The TRR represents the speed at which the thermocycler heats up and cools down between PCR steps, which is inversely proportional to the time. Considering the technical capabilities of the thermal cycler used (T100; BIO-RAD, USA), ramp rates ranging from 0.6 to 2.2 °C/s were tested. Higher ramp rates resulted in shorter overall reaction times. Notably, a 30-minute PCR using the highest TRR (2.2 °C/s) and holding times of 1 s amplified comparably to the conventional PCR, as positive control (Fig 2A). Based on these results, this value was selected for subsequent assays, as higher values were not evaluated due to minimally expected improvements in time efficiency. To further assess the method’s robustness, a less processive, in-house-produced DNA Taq polymerase was evaluated under the same TRR conditions. Given the enzyme’s lower processivity and polymerization rate (nt/s), each PCR step holding-time was extended to 10 s instead of 1 s, based on a prior time optimization curve (S2 Fig in S1 Text). This adjustment increased the total assay time by 14 minutes but still resulted in comparable amplification across all TRR values tested (Fig 2B). Amplification products obtained using a PCR with modified thermal cycling (PCRmod). Amplified 282-bp sequences were visualized using an agarose gel (1.7%) alongside a 100-bp ladder. Standard PCR (PCRstd) was used as a positive amplification reaction (C+). (A) DNA amplification using a commercial DNA Taq polymerase using different TRR values: 0.6, 0.8, 1.2, 1.6, and 2.2 °C/s. After each ramp 1 s was used as hold or extension time. Total PCR time is indicated for each TRR. Each condition was tested also in the absence of the template DNA (-). (B) As A using a locally produced DNA Taq polymerase and 10 s for hold or extension time. Another variable considered during standardization was the product size as longer products require longer extension (or hold) time. In all assays shown, a 282-bp amplicon size was the final amplification product. Nonetheless, a longer product of 564 bp was also tested. The TRR gradient yielded comparable results using the commercial enzyme (S3 Fig in S1 Text), maintaining the overall turnaround time. CRISPR-Cas assay for detection of amplified ARG targets CRISPR-Cas systems have been used to detect DNA or RNA targets under different types of readouts. Here a fluorescent CRISPR-Cas-based readout was coupled to the modified PCR to detect the blaOXA-1 gene in the E. coli genome. The selected crRNA in the CRISPR-Cas reaction showed a high target discrimination when genomic DNA was amplified using the modified PCR. Target detection was observed from 10 min onwards, reaching a normalized fluorescent ratio of 10 a.u. at 20 min of assay reading (Fig 3). Direct fluorescent visualization also allowed discrimination between positive and negative reactions (Fig 3A). A cutoff value of 1.92 a.u. at 20 min was estimated for the assay under optimized conditions (S4 Fig in S1 Text). The assay showed full specificity for blaOXA-1 sequence, when compared to other beta-lactamases (S5 Fig in S1 Text). Assay optimization and performance evaluation. (A) Discrimination assay ability. Normalized fluorescent ratio values (NFntc) are plotted over time for a positive sample (POS) and a non-template control (NTC). The inset image shows the fluorescence of the POS and NTC reactions as observed with a blue-light transilluminator. (B) Analytical sensitivity of the optimized assay. The assay response to decreasing target quantity is plotted as NFntc values over target quantity expressed in logarithmic scale of total moles of a purified 564-bp amplicon. Error bars indicate the SEM value from the mean from duplicates. (C) Thermal cycling performance comparison. The heatmap shows the target detection performance between reactions using a commercial DNA polymerase (DreamTaq) in the modified PCR protocol (PCRmod) (left lane), a locally produced polymerase (TaqLab – mid and right late) in the modified PCR protocol (midlane), and in a standard PCR protocol (PCRstd) (right lane). Color intensity corresponds to the NFntc values at each DNA template concentration that was evaluated (N = 36). (D) Spiking assay using a blaOXA-1-positive E. coli in a poultry feces sample. The assay was evaluated against a non-spiked control (NEG) and samples spiked with 8 or 60 CFU per reaction (n = 4). The horizontal line in each group represents the mean NFntc value. For all panels, the dotted line in the Y-axis represents the NFntc cutoff to discriminate positive from negative samples at 20 min. The dotted line in the X-axis represents the selected reading time for the CRISPR-Cas assay. The modified PCR in combination with the fluorescent CRISPR-Cas reaction was able to detect 5.12 x 10−3 attomoles of a linear target per reaction, yielding a normalized fluorescence mean (NFntc) value of 2.07, which represents a minimal increase over the determined cutoff. By contrast, a 5-fold higher target quantity (2.56 x 10−2 attomoles per reaction) produced an NFntc value of 5.88, corresponding to approximately 2-fold higher signal relative to the cutoff. Accordingly, the LoD was estimated to be 5 x 10−3 attomoles, consistent with the lowest target quantity that differs from the blank. For better comparison, this target quantity is equivalent to 3000 gene copies (Fig 3B). To further evaluate the assay performance, a locally produced Taq DNA polymerase was tested with the modified amplification cycling. Compared to the modified PCR amplification with the commercial polymerase, the in-house enzyme detects 600-fold lower target concentration. However, when amplification protocols were compared using only the in-house enzyme, minimal differences were observed (Fig 3C, mid and right lane). The lowest target quantity detected with the locally produced enzyme was 3.2 attomoles per reaction, regardless of the amplification protocol. However, a 2-fold higher signal was observed for the standard PCR amplification (Fig 3C). Finally, bacterial cell detection was evaluated by spiking poultry feces samples. Using a commercial DNA Taq polymerase, the optimized assay enables detecting 60 CFU, yielding a mean NFntc value of 10.85. In contrast, a 7-fold lower CFU produced only a marginal increase over the negative control, reaching a mean NFntc value of 2.23. Taken together, our results demonstrate that the described assay is competitive in terms of analytical sensitivity for detecting biological markers such as antimicrobial resistance genes even in simulated samples. Discussion Extended- and narrow‑spectrum β‑lactamases remain a major concern in clinical microbiology due to their prevalence, diversity, and global distribution [2,39]. Among these, the blaOXA-1-like gene has been reported in multiple bacterial families, including Enterobacteriaceae, Moraxellaceae, and Pseudomonadaceae [40], which include most members of the ESKAPE group. Recent studies highlight high frequencies exceeding 50% in clinical Klebsiella pneumonia isolates [4], and its identification as the most abundant plasmid-borne blaOXA gene (57.93%) among E.coli isolates [5] regardless of geographical region. The blaOXA-1 gene is frequently associated with class 1 integrons and often co‑occurs with other resistance determinants, such as aminoglycoside-resistance genes like aac(6’)-lb-cr, other carbapenemases, and even colistin-associated resistance genes [5]. These findings highlight the clinical and epidemiological significance of the blaOXA gene families. In this study, we developed and evaluated a rapid molecular assay for blaOXA-1-like gene detection, combining a faster PCR protocol with CRISPR‑Cas fluorescence readout. With this approach, amplification time was reduced to 30 min, representing a 62.5% decrease compared to conventional PCR. Thus, the complete workflow, from amplification to CRISPR‑Cas detection, is completed in 50 minutes. With a commercial DNA Taq polymerase, the assay achieved a detection limit of 5 x 10−3 attomoles of pure DNA. When tested with simulated samples, it reliably detected ≥60 CFU per reaction, with a marginal signal at 8 CFU per reaction, equivalent to two-fold above negative controls. It is important to emphasize the value of evaluating assay sensitivity using metrics that reflect real-world conditions, such as CFU numbers. Since ARGs are primarily disseminated through bacterial hosts in clinical and environmental settings, biological titters provide a more relevant assessment of detection performance than purified DNA concentrations alone. CRISPR-Cas-based assays are characterized by a two-level specificity, one determined by primer annealing, and the other by the crRNA binding. Although assay specificity was not evaluated in vitro, our in silico analysis indicated a high expected specificity. LbCas12a can tolerate mismatches depending on their distance from the PAM. The first five nucleotides adjacent to the PAM constitute the seed sequence, which is essential for Cas12a activity [41]. Mismatches close to the PAM have stronger effects; for example, a mismatch at position +1 abolishes target recognition, whereas a mutation at position +5 partially reduces template recognition [42]. After position +5, nucleotide variation is generally tolerated; however, at least 17 out of 22 nucleotides (77%) must match for Cas12a-mediated cleavage to occur. blaOXA groups other than group 1 did not exhibit such level of complementarity with either the designed crRNA or the primers, thus it is expected that our system should not detect them. Our results compare favorably with other CRISPR‑Cas‑based β‑lactamase detection assays. Recently, a PCR–Cas12a system for blaOXA-1 was reported, with a 70‑minute turnaround (65 minutes amplification followed by 5 minutes detection) and a limit of 1.25 gene copies [40]. However, their assay differs from ours in several reaction parameters, including temperature (25 °C vs. 37 °C), reaction buffer (NEB r2.1 vs. Holmes), and fluorescent probe design (TTATT vs. 8C or hairpin ssDNA), exemplifying the diversity of published assay protocols. Other studies have targeted blaGES, blaNDM-1, blaOXA-23, blaOXA-41, and blaOXA-48 using isothermal amplification (RPA, LAMP) with LbCas12a or LwaCas13a, reporting turnaround times of 60–120 minutes and diverse limits of detection such as 1.3 x 10−6 ng/μL [43], 2.7 CFU/ml [44], and species-dependence range such as 103–10⁷ CFU/mL [45]. Such methodological variability complicates direct performance comparisons, yet our assay is competitive in terms of speed, sensitivity, and resource requirements. From an implementation perspective, conventional PCR remains widely used albeit requiring a thermocycler and longer run times. Isothermal methods such as LAMP and RPA offer faster amplification without thermal cycling but can suffer from nonspecific amplification [46], limited reagent availability [47], and insufficient validation in clinical matrices [48]. Unlike current molecular methods for detecting blaOXA genes, such as PCR, qPCR or NGS, which are time-consuming or require specialized equipment, our CRISPR-Cas-based assay provides a rapid fluorescent readout compatible with low-cost, portable tools such as blue-light transilluminator or 3D-printed fluorometers, bypassing the necessity of expensive and additional instrumentation such sequencers, real-time thermocyclers, or electrophoresis chambers, enabling future democratization of CRISPR-Cas-based molecular detection assays. Although the principal limitation of our study is the absence of real sample validation, our approach still offers a balanced alternative, maintaining high analytical sensitivity while reducing turnaround time and relying on equipment common to most basic molecular laboratories. Our system could find a compelling advantage against traditional molecular detection platforms if applied for environmental monitoring of ARG due to its velocity, low cost, and compatibility with minimal equipment. When using an in‑house-produced DNA Taq polymerase, amplification time increased by 15 min, due to the need for ≥ 10-s holds at each temperature step during amplification. This may reflect suboptimal buffer composition or reagent concentrations. Sensitivity was also reduced, with a detection limit of 3.2 attomoles—over 600‑fold less sensitive than the commercial enzyme. However, when comparing both PCR amplification protocols (e.g., standard vs modified thermal cycling) with the in‑house enzyme, the detection limit differed by only five‑fold, consistent with Chen’s findings that amplification strategy may have less impact than enzyme quality [38]. While further optimization is needed, the use of locally produced enzymes remains a strategic option for mitigating supply chain disruptions, as seen during the COVID‑19 pandemic [49]. In conclusion, the proposed assay expands the toolkit for ARG gene detection, particularly in low‑resource settings where basic molecular equipment is available. Its combination of speed, sensitivity, and adaptability makes it a promising candidate for further validation. Conclusion We proposed a proof-of-concept assay that combines modified thermal cycling–PCR with fluorescent CRISPR-Cas detection. This approach significantly reduces the total turnaround time for detecting antimicrobial resistance genes using basic molecular biology equipment. The assay, when using commercially available enzymes, retains competitive analytical sensitivity. However, further validation is required to confirm its diagnostic value. Supporting information Multiple sequence alignment of the DNA sequences retrieved from the CARD and NDARO databases related to the blaOXA-1 gene. (ALN) Multiple sequence alignments of the DNA sequences retrieved from the CARD and NDARO databases related to the non-blaOXA-1 groups. (ZIP) Original uncropped and unadjusted images of agarose gels. (PDF) Supplementary figures. (DOCX) 3 Feb 2026 -->PONE-D-25-60550-->-->Thermal optimized PCR coupled to CRISPR-Cas12a for rapid detection of blaOXA-1 resistance gene-->-->PLOS One Dear Dr. Alcántara, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== -->-->The reviewer has pointed out a number of areas in which revision is needed. Please addess all reviewer comments point by point.-->-->============================== Please submit your revised manuscript by Mar 20 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Iddya Karunasagar Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. Thank you for stating in your Funding Statement: “This research was supported by a research grant from the Universidad Peruana de Ciencias Aplicadas with number C-004-2021-1 awarded to Roberto Alcántara.” Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 3. Thank you for stating the following financial disclosure: “This research was supported by a research grant from the Universidad Peruana de Ciencias Aplicadas with number C-004-2021-1 awarded to Roberto Alcántara.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. 5. Please be informed that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): Please see reviewer comments and revise the manuscript accordingly. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: I Don't Know Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Thermal optimized PCR coupled to CRISPR-1 Cas12a for rapid detection of blaOXA-1 resistance gene This study developed a CRISPR-Cas12a-based fluorescence method for the detection of blaOXA-1 gene, with a sensitivity of 8 CFU. Primers designed from consensus sequences of blaOXA-1 were employed in conventional PCR for initial optimization of conditions, followed by CRISPR-Cas detection. Major comments The study does not convincingly prove the specificity of the assay. The authors should have tested their primers with diverse blaOXA-1-harbouring isolates, both E. coli and other Enterobacterales, and other ESBL- and MBL-encoding genes to prove the specificity of the method developed. What is the specific advantage of this method, when PCR methods for blaOXA variants are already available? Further, the authors need to clearly define the goal (s) and the application of their work in the abstract and in the introduction section. It is only evident after section 2.4.3. (Spike-in pilot test) that the method was indeed designed to detect the target organisms (E. coli carrying blaOXA-1 gene) in chicken feces. In L217-223: It is stated here that the mismatches in primer binding sites might potentially affect detection of the variants of blaOXA gene. This being the case, is this method specific to only blaOXA-1 gene? Does this not limit the application of this method, since blaOXA genes are very diverse? L165: Here, amplification product of 564 bp has been mentioned. What does this product refer to? 5 x 10-3 attomoles of pure DNA: Please compare and discuss the sensitivity with pure DNA and the spiked bacterial cells (8 CFU/reaction). Alternatively, this may be represented as gene copies. Minor comments Please label A & B in Figure 2 Figure 3. Please move (A) to the next line Reviewer #2: The study is simple yet performed with relevant outcomes. However, authors can address the following comments 1. What is the inclusion/exclusion criteria used while selecting 46 blaOXA-1 gene sequences? 2. Authors need to specify the version of tools used and parameter settings wherever applicable throughout the methodology 3. Times reported for different TRR with lab-made Taq (e.g., 0.6 °C/s = 83 minutes) differ from those with DreamTaq. Can authors clarify why total run times differ, given similar cycle numbers and temperatures? 4. Can authors provide alternative gel image for Figure 2A since the bands appear at different size range (could be due to imaging error) 5. Two different plate readers were used. Were the instruments cross-calibrated to ensure comparable fluorescence readings? 6. How was 10 blaOXA-1 negative E. coli isolates confirmed? Whether by PCR or WGS? 7. Authors used a 564 bp purified amplification product as target for Target concentration curve. Why is this length different from the 282 bp region described earlier? 8. For amplification with lab-made enzyme cycle time was 10 s per step, while 1 s protocol was followed for DreamTaq. Can authors justify the difference? 9. During spike test, OD600 was adjusted to 0.05 before serial dilutions. Was CFU conversion calibrated for this isolate or assumed from literature? 10. “From each selected dilution, 100 μL were transferred to 900 μL of the fecal suspension, then, 250 μL of each suspension was used for total DNA extraction, corresponding to an estimated 8 and 60 total CFUs, respectively.” Was extraction efficiency (recovery of DNA per CFU) evaluated or assumed? 11. “Extraction was performed using the ZymoBIOMICS™ DNA Miniprep Kit (Cat. N° D4300, Zymo Research), following the manufacturer's protocol.” Could authors compare kit-based extraction to simpler or cheaper methods that may be relevant for field deployment? 12. For spiked samples, authors used the modified PCR with DreamTaq and subsequent CRISPR detection. Did authors also test lab-produced Taq in the fecal matrix, and if not, why? ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 3 Mar 2026 Thank you for your comments and suggestions. We have carefully considered each requirement and implemented the changes that enhance the quality of the manuscript. Submitted filename: Response_to_reviewers.docx 8 Apr 2026 -->PONE-D-25-60550R1-->-->Thermal optimized PCR coupled to CRISPR-Cas12a for rapid detection of blaOXA-1 resistance gene-->-->PLOS One Dear Dr. Alcántara, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Some minor changes in language improvement, formattig needed ============================== Please submit your revised manuscript by May 23 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Iddya Karunasagar Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments : Please see some comments from reviewer regarding improvements needed. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The authors have responded to the queries raised in the previous review. Yet, the application of blaOXA-1 group -specific detection method has limited applicability in view of the fact that this does not cover the most common blaOXA gene(s) either in E. coli or other Gram-negative pathogens such as Acinetobacter baumannii. The application of an in-house polymerase is something unique in this study, although it is not clear how the results obtained using an in-house polymerase can be reproduced in other laboratories beyond the geographic region where this study was performed. Further, the authors have stated in the manuscript that this polymerase had a lower efficiency (processivity) compared to commercial polymerase (s). In my opinion, the section describing in-house polymerase may be removed, as the data/results are relevant only to the laboratory employing it. A few suggestions are below for authors’ consideration 75: Please correct as ..”needing long amplification times. L96-97: Please rephrase this sentence. Please write blaOXA correctly throughout the manuscript. OXA should be subscript of bla and in non-italics. L133: The dNTP concentration of 0.5 nM seems to be too low. Please check. Similarly, the Taq concentration is generally stated in units, but you have indicated in ng/µL. L163-164: Please write bla genes in correct format. L208: Please provide the strain number/designation of blaOXA-1 isolate you used in this study L208: Replace “cultivated” with “grown” L211: Seeded? It appears that you performed a spread plate. However, spread plate method employs 100 microliters, not 50. L214-216; Please rephrase the sentence. L446-451: Agreed that qPCR and NGS are expensive. In what way your method is less expensive or technically less demanding than conventional PCR?. This method also requires PCR amplification, followed by fluorescence detection. Reviewer #2: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 28 Apr 2026 Minor changes have been resolved as requested. Regarding to the Reviewer #1 comments: "The authors have responded to the queries raised in the previous review. Yet, the application of blaOXA-1 group -specific detection method has limited applicability in view of the fact that this does not cover the most common blaOXA gene(s) either in E. coli or other Gram-negative pathogens such as Acinetobacter baumannii." Thank you for this perspective. We agree that blaOXA genes are remarkably diverse and that different variants are more prevalent depending of the host species, geographical area and clinical/environmental context. However, we maintain that blaOXA-1 represents a priority target for the following reasons: • High prevalence in other clinically relevant Gram-negative: Recent literature confirms high frequencies exceeding 50% in clinical Klebsiella pneumoniae isolates (Meng et al., 2023), and identifying blaOXA-1-carrying plasmids as the most abundant (57.93%) in E. coli isolates (Wu et al., 2024). In both studies, independently of the geographic area. • Co-presence with other ARG markers: blaOXA-1 is frequently associated with class 1 integrons and co-occurs with other relevant resistance markers such as blaXTX-M-15 and aac(6’)-Ib-cr. • Presence in environmental and food samples: Some studies have reported high prevalence of blaOXA-1 in soil and manure samples, 45.16% (Laconi et al., 2021), and in E.coli isolated from poultry meat, 40.54% (Ali 2025). Finally, we acknowledge that this assay does not cover all relevant and high frequent OXA-carbapanemases. However, as a proof-of-concept, we intended to develop a rapid, user-friendly and affordable tool for monitoring this emerging resistance gene. These statements and references have been added to the manuscript. "The application of an in-house polymerase is something unique in this study, although it is not clear how the results obtained using an in-house polymerase can be reproduced in other laboratories beyond the geographic region where this study was performed. Further, the authors have stated in the manuscript that this polymerase had a lower efficiency (processivity) compared to commercial polymerase (s). In my opinion, the section describing in-house polymerase may be removed, as the data/results are relevant only to the laboratory employing it." Thank you for your perspective. We maintain that including the local-produced DNA polymerase results is important for contributing to the democratization of molecular diagnostics. By providing full standardized protocols (Reference 30) and evidence of their implementation, we demonstrate that molecular detection can be achieved based on local efforts. Although the Taq DNA polymerase showed a lower performance compared to a commercial alternative, its inclusion serves as a proof-of-concept for local enzyme production. We stated that further optimization is needed and does not discard the utility of local-produced enzymes for implementing molecular detection assays, even in emergency contexts such as future pandemics as we stated in lines 468-470. Submitted filename: Response to reviewers.docx 3 May 2026 Thermal optimized PCR coupled to CRISPR-Cas12a for rapid detection of blaOXA-1 resistance gene PONE-D-25-60550R2 Dear Dr. Alcántara, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Iddya Karunasagar Academic Editor PLOS One Additional Editor Comments (optional): All reviewer comments have been addressed. Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The authors have satisfactorily addressed all the queries raised in the previous review. L263-265 & ub Figure legends: Italicize "bla". Fig 2B legend: "Same as A, using... Fig. 3B: the x axis lebel say "target log1o attomoles, but the numbers are represented to the power of 10. Please check if this is correct. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No ********** PONE-D-25-60550R2 PLOS One Dear Dr. Alcántara, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Iddya Karunasagar Academic Editor PLOS One